Therapy of XXXX .

@entity1 @entity5257 @entity5699 @entity2592 @entity3052 @entity1778
Over the past 10 years, there have been substantial advances in the treatment of @entity3052 . Intensive induction chemotherapy using 7-day courses of @entity2592 and @entity5699 or @entity5257 produce remission in 60% to 85% of @entity1 . Median remission duration is 9 to 16 months. In some series, 20% to 40% of @entity1 are in continuous remission for 2 years or more; many of these @entity1 remain in remission for 5 years or longer and some may be cured. Bone marrow transplantation has evolved as a useful therapeutic modality capable of achieving long-term survival in some circumstances in which chemotherapy is relatively ineffective. Its precise role in the initial therapy of @entity3052 remains to be defined, but it is likely to be beneficial in selected @entity1 . These data indicate substantial recent progress in the treatment of this disease, which was almost uniformly fatal 30 years ago. The fact that most @entity1 relapse within 1 to 2 years reflects a lack of progress in developing effective postremission therapy. Maintenance chemotherapy, immunotherapy, and CNS prophylaxis have little role in @entity3052 . It is unclear whether consolidation or intensification extend remissions or increase the proportion of long-term survivors; controlled randomized trials should answer this question within the next few years. Future progress in the treatment of @entity3052 awaits the development of more sensitive methods for detecting @entity1778 , more effective use of current therapeutic modalities and the introduction of new effective drugs. Most data suggest that early intensive treatment is of key importance for achieving cures. However, we cannot presently distinguish between @entity1 cured by initial treatment and those who required further chemotherapy.
